KRYS · CIK 0001711279
What Krystal Biotech, Inc. told the SEC could break it.
Krystal Biotech's disclosures are defined by concentration in a single product and a single buyer: its revenue and future growth are substantially dependent on the commercial success of one product, VYJUVEK for dystrophic epidermolysis bullosa, and a single U.S. customer generated about 75% of net product revenue in 2025, with no other customer above 10%. Its path to broadening that base runs through protracted European pricing and reimbursement negotiations — ongoing in Germany into the second half of 2026 and France through 2027, with Italy and others pending — and it relies on a small number of third parties to distribute VYJUVEK in the U.S., along with third-party manufacturers and key suppliers for biologic raw materials.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- single U.S. customer = 75% of product revenuehigh
A single U.S. customer generated ~75% of Krystal's net product revenue in 2025 (87% in 2024, 100% in 2023), with no other customer above 10% — an extreme customer concentration.
“For the years ended December 31, 2025, 2024, and 2023, approximately 75 %, 87 % and 100 %, respectively, of the Company's product revenue, net was generated from a single customer in the U.S. No other customer exceeded 10% of the Company's product revenue, net.”
SEC filing →As of 2026
Other disclosures
- single-product dependence on VYJUVEKhigh
Krystal's revenue, growth and ability to fund its pipeline are substantially dependent on the commercial success of a single product, VYJUVEK (for dystrophic epidermolysis bullosa).
“our ability to develop our product candidates and generate revenue, and our future growth are substantially dependent on the commercial success of VYJUVEK.”
SEC filing →As of 2026
Regulatory & policy
- EU drug pricing & reimbursement negotiations (Germany/France/Italy)medium
Krystal's European VYJUVEK economics depend on protracted country-by-country pricing/reimbursement negotiations — ongoing in Germany (through 2H 2026) and France (through 2027), with Italy and other markets pending.
“Pricing negotiations are underway in both Germany and France and are expected to continue until at least the second half of 2026 in Germany and until 2027 in France.”
Supplier concentration
- small number of third-party distributors/packagers/logistics for VYJUVEKmedium
Krystal relies on a small number of third parties to distribute VYJUVEK in the U.S. — a third-party packaging company, a third-party logistics provider, and a limited number of specialty pharmacies — plus third-party manufacturers and key suppliers for biologic raw materials.
“We rely on a small number of third parties to commercially distribute VYJUVEK to patients in the United States. We have contracted with a third-party packaging company to package VYJUVEK, a third-party logistics company to warehouse, process, and ship VYJUVEK to a limited number of specialty pharmacies”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch